<DOC>
	<DOCNO>NCT01157065</DOCNO>
	<brief_summary>The primary purpose study demonstrate biological effect AL-78898A , measure change ( reduction ) central subfield ( CSF ) retinal thickness 4 week single intravitreal injection , compare LUCENTIS .</brief_summary>
	<brief_title>Evaluation AL-78898A Exudative Age-Related Macular Degeneration</brief_title>
	<detailed_description>The study consist Screening Visit ( Visit 1 ) , Day 0 visit ( Visit 2 ) , 6 on-therapy visit Day 1 , Weeks 1 , 2 , 3 , 4 , 8 ( Visits 3-8 ) , Exit Visit Week 12 ( Visit 9 ) . Patients meet inclusion exclusion criterion Visit 1 randomize 3:1 ratio receive either AL-78898A LUCENTIS single 50-Î¼L injection study eye . Additionally , patient receive standard therapy exudative AMD begin Week 2/Visit 5 patient improve per protocol-specified criterion . Beginning Week 4/Visit 7 , patient improve received standard therapy exudative AMD investigator 's discretion .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Willing give inform consent , make require study visit follow instruction ; Newly diagnose exudative agerelated macular degeneration ( AMD ) ; Presence primary juxta subfoveal choroidal neovascularization ( CNV ) secondary AMD ( study eye ) ; Bestcorrected visual acuity ( BCVA ) study eye specify protocol ; No visionthreatening ocular condition AMD , opinion Investigator ; Other protocolspecified inclusion criterion may apply . History current evidence macular retinal disease exudative AMD ( study eye ) ; Any evidence fibrosis scar within CNV ( choroidal neovascularization ) lesion ( study eye ) ; Any evidence vitreous hemorrhage ( study eye ) ; History evidence surgery ( study eye ) , specify protocol ; Any active systemic infection ocular/intraocular infection inflammation either eye ; A history current medical diagnosis glaucoma ocular hypertension ( study eye ) , specify protocol ; History current evidence medical condition may opinion Investigator preclude safe administration test article , adherence schedule study visit , safe participation study affect result study History severe serious hypersensitivity component investigational product , reference product clinically relevant sensitivity fluorescein dye , assessed Investigator ; Females childbearing potential may participate study pregnant , lactating , use adequate birth control method duration study ; Participation ocular nonocular investigational study within 30 day screen ; Has receive approve investigational therapy AMD study eye exception vitamin ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Wet AMD</keyword>
	<keyword>Intravitreal Injection</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>VEGF treatment</keyword>
</DOC>